Completed × Carcinoma, Transitional Cell × Thoracic × Clear all Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Phase 1 Completed
146 enrolled 38 charts
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Phase 1/2 Completed
45 enrolled 30 charts
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Phase 1/2 Completed
40 enrolled 11 charts
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1/2 Completed
34 enrolled 14 charts
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Phase 1/2 Completed
323 enrolled
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Phase 1 Completed
175 enrolled 23 charts
DUET-3
Phase 1 Completed
198 enrolled
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
35 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
CHEERS
Phase 2 Completed
99 enrolled
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Phase 2 Completed
100 enrolled 14 charts
A Study of a Personalized Neoantigen Cancer Vaccine
Phase 1/2 Completed
29 enrolled
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Phase 1 Completed
11 enrolled
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Phase 1 Completed
19 enrolled
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Phase 1 Completed
12 enrolled
DUET-4
Phase 1 Completed
78 enrolled
PIVOT-02
Phase 1/2 Completed
557 enrolled 22 charts
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
DUET-2
Phase 1 Completed
150 enrolled
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Phase 1/2 Completed
24 enrolled
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Phase 2 Completed
1 enrolled
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Phase 1 Completed
6 enrolled 27 charts
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
A Study of Personalized Neoantigen Cancer Vaccines
Completed
93 enrolled
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Phase 1 Completed
169 enrolled
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Phase NA Completed
52 enrolled
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase 1 Completed
37 enrolled